The legitimacy of broad, mutually beneficial cooperation in the field of innovation development between pharmaceutical and biotechnology companies and scientists, students, and innovators seems indisputable. And yet, talks about joint, ambitious R&D projects often remain in the declaration phase. Why is this happening and what can be done about it to fully use the potential of BigPharma’s cooperation with the innovation ecosystem?